Skip to content

Diagnostic continuous glucose monitoring to improve the care of pediatric patients with hypocortisolism

Diagnostic continuous glucose monitoring to improve the care of pediatric patients with hypocortisolism - Cort-CGM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00033148
Enrollment
20
Registered
2024-08-13
Start date
2024-07-27
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypocortisolism, adrenal insufficiency E27

Interventions

Group 1: Children and adolescents aged 2 to 17 with primary or secondary adrenal insufficiency and continuous cortisone replacement therapy wear a continuous glucose monitoring system after informed c

Sponsors

Universitätsklinikum Düsseldorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of central or primary adrenal insufficiency. Hypocortisolism should be treated permanently (for 3 months) with hydrocortisone or another cortisone preparation

Exclusion criteria

Exclusion criteria: Acute derailments during the last 7 days. Patients with congenital adrenal hyperplasia (CAH) will not be able to participate.

Design outcomes

Primary

MeasureTime frame
To investigate the effect of intermediate diagnostic, blinded continuous glucose monitoring (CGM) use in children and adolescents with primary or secondary adrenal insufficiency. After a regular appointment in the outpatient clinic and starting the CGM sensor, continuous glucose data are recorded over 10 days in everyday life. The primary outcome is the detection of otherwise unnoticed hypoglycemia (timing, duration, and frequency). While wearing the CGM, ketone measurements in morning urine are performed to rule out ketotic hypoglycemia. CGM data are downloaded at a second appointment after 10 days.

Secondary

MeasureTime frame
Analysis of the frequency, timing, and duration of hyper- and hypoglycemic events and ketonuria during 10 days of continuous glucose monitoring, also in relation to treatment data.

Countries

Germany

Contacts

Public ContactChristina Reinauer

Universitätsklinikum Düsseldorf

christina.reinauer@med.uni-duesseldorf.de+492118117663

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026